Quote from a real EMPAVELI patient.

Quote from a real EMPAVELI patient.
Image is an actor portrayal.

EMPAVELI was studied vs eculizumab in a head-to-head Phase 3 clinical trial in 80 people living with PNH. Compared to the beginning of the study, people taking EMPAVELI had a 2.37 g/dL increase in hemoglobin levels compared to a 1.47 g/dL decrease with eculizumab at Week 16. EMPAVELI showed a superior 3.84 g/dL difference in Hb levels vs eculizumab (P<0.0001).

Before, I could not make travel plans

Quote from a real EMPAVELI patient.
Image is an actor portrayal.

EMPAVELI was studied vs eculizumab in a head-to-head Phase 3 clinical trial in 80 people living with PNH. Compared to the beginning of the study, people taking EMPAVELI had a 2.37 g/dL increase in hemoglobin levels compared to a 1.47 g/dL decrease with eculizumab at Week 16. EMPAVELI showed a superior 3.84 g/dL difference in Hb levels vs eculizumab (P<0.0001).

Support that serves your treatment needs
Apellis Assist Always at your side
ApellisAssist is a program designed to help you along your treatment journey

Every person with PNH is unique and has their own needs when starting a new treatment. That is why ApellisAssist was
created—to provide a comprehensive support system that’s always with you during your treatment journey.

This program provides services and resources including:

Financial assistance for
eligible patients
Insurance
support
Self-infusion
training
EMPAVELI and
PNH education

As you prepare to start treatment with EMPAVELI, you will collaborate with your Care Team, comprised of your Care Coordinator, through our specialty pharmacy, PANTHERx Rare, and an Apellis Care Educator. Together, you will make decisions tailored to you, such as:

  • Your preference for in-person or telehealth self-infusion training
  • Your preference of communication style
  • Your desired frequency of calls or text reminders
Care Coordinator

A dedicated coordinator who will work with you one-on-one to help:

  • Explain your insurance benefits and coverage options
  • Review available financial assistance programs
  • Manage product and infusion supply shipments
Apellis Care Educator

A compassionate care partner with a nursing background who will help:

  • Provide in-person or virtual training and education on how to self-infuse EMPAVELI
  • Address questions about EMPAVELI or PNH
Have insurance questions?
We can figure this out together
Together, we can help you understand your insurance and coverage options.
Once enrolled in ApellisAssist, you may be eligible for one of the financial assistance programs below.
Call ApellisAssist at
1-866-MY-APL-ASSIST

(1-866-692-7527)(1-866-692-7527) to speak with your Care Coordinator
and learn more about these programs
Apellis Co-Pay Program The Apellis Co-Pay Program for patients with commercial insurance is available to help cover your co-pay and co-insurance costs. Enroll in ApellisAssist today to see if you’re eligible
for this program.*
The Apellis Co-Pay Program is for eligible patients who are enrolled in the ApellisAssist program, are commercially insured, and who are not covered under government insurance programs such as Medicaid, VA/DoD, or TRICARE. Program terms are subject to change.
Apellis Patient Assistance Program
If you don’t have insurance or your insurance only provides limited coverage, the Apellis Patient Assistance Program may be able to help you obtain EMPAVELI at no cost.
In order to be eligible for the Apellis Patient Assistance Program, you must:
  • Be diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) in accordance with the approved EMPAVELI indication
  • Be enrolled in ApellisAssist
  • Have no insurance or be underinsured
  • Have a prescription for EMPAVELI
  • Currently live in the US or a US territory
  • Meet financial eligibility criteria
Apellis Bridge Program
The Apellis Bridge can help with interruptions or changes in insurance. If your insurance provider has changed or your plan has changed, you may experience an interruption in coverage. If this occurs, you could be eligible for a temporary supply of EMPAVELI through the Apellis Bridge Program.*
Terms and Conditions apply.
Call at
1-866-MY-APL-ASSIST (1-866-692-75271-866-692-7527)
from 8AM-8PM ET, MONDAY-FRIDAY
Discover resources and support tools
learn more
Image is an actor portrayal.
INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND IMPORTANT SAFETY INFORMATION

What is EMPAVELI (pegcetacoplan)?

EMPAVELI is a prescription medicine used to treat adults with a disease called paroxysmal nocturnal hemoglobinuria (PNH).

What is the most important information I should know about EMPAVELI?

EMPAVELI is a medicine that can affect your immune system and can lower the ability of your immune system to fight infections.

  • EMPAVELI may increase your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.
  • EMPAVELI may also increase the risk of getting serious infections caused by certain bacteria such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Serious infections may quickly become life-threatening and cause death if not recognized and treated early.
  1. You must be vaccinated against these bacteria at least 2 weeks before your first dose of EMPAVELI if you have not already had these vaccines.
  2. If your healthcare provider decides that urgent treatment with EMPAVELI is needed, you should receive the required vaccinations as soon as possible.
  3. If you have not been vaccinated and EMPAVELI therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
  4. If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting EMPAVELI. Your healthcare provider will decide if you need additional vaccinations.
  5. Vaccines reduce the risk of serious infections, but do not prevent all serious infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:
    • fever with or without shivers or the chills
    • fever and a rash
    • shortness of breath
    • extreme pain or discomfort
    • headache with nausea or vomiting
    • high heart rate
    • headache and a fever
    • headache with a stiff neck or stiff back
    • confusion
    • muscle aches with flu-like symptoms
    • clammy skin
    • eyes sensitive to light

Your healthcare provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 months after your last EMPAVELI dose. It is important to show this card to any healthcare provider to help them diagnose and treat you quickly.

EMPAVELI is only available through a program called the EMPAVELI Risk Evaluation and Mitigation Strategy (REMS). Before you can take EMPAVELI, your healthcare provider must enroll in the EMPAVELI REMS program, counsel you about the risk of serious infections caused by certain bacteria, give you information about the symptoms of serious infections, give you a Patient Safety Card about your risk of serious infections, and make sure that you are vaccinated.

Who should NOT take EMPAVELI?

Do not take EMPAVELI if you:

  • are allergic to pegcetacoplan or any of the ingredients in EMPAVELI.
  • have not been vaccinated against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B, unless your healthcare provider decides that urgent treatment with EMPAVELI is needed.
  • have a serious infection caused by the bacteria above.

Before you take EMPAVELI, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • are pregnant or plan to become pregnant. EMPAVELI may harm your unborn baby. Females who are able to become pregnant should have a pregnancy test before starting treatment with EMPAVELI and use an effective method of birth control during treatment with EMPAVELI and for 40 days after the final dose.
  • are breastfeeding or plan to breastfeed. It is not known if EMPAVELI passes into your breast milk. You should not breastfeed during treatment with EMPAVELI and for 40 days after the final dose.

Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

If you stop taking EMPAVELI, your healthcare provider will need to monitor you closely for at least 8 weeks after stopping EMPAVELI. Stopping treatment with EMPAVELI may cause a breakdown of red blood cells due to PNH.

Symptoms or problems that can happen due to red blood cell breakdown include:

  • decreased hemoglobin level in your blood
  • blood in your urine
  • shortness of breath
  • trouble swallowing
  • tiredness
  • pain in the stomach (abdomen)
  • blood clots
  • erectile dysfunction (ED)

What are the possible side effects of EMPAVELI?

EMPAVELI can cause serious side effects including allergic reactions. Allergic reactions can happen during your EMPAVELI infusion. Stop your EMPAVELI infusion and tell your healthcare provider or get emergency medical care right away if you get any of these symptoms during your EMPAVELI infusion:

  • chest pain
  • trouble breathing or shortness of breath
  • swelling of your face, tongue, or throat
  • feel faint or pass out

The most common side effects in people with PNH treated with EMPAVELI include injection-site reactions, infections, diarrhea, pain in the stomach (abdomen), respiratory tract infection, viral infection, and tiredness.

These are not all of the possible side effects of EMPAVELI. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Boxed WARNING regarding risk of serious infections, and Medication Guide for additional information.